Objective:To observe the effects of hyperbaric oxygen combined with Xingnaojing injection on serum nerve injury，serum factors，and cognitive function in patients with acute carbon monoxide poisoning delayed encephalopathy（ACMPDE）.Methods:A total of 106 cases with ACMPDE who were admitted to the First People’s Hospital of Nanning from July 2018 to July 2020 were selected as the research subjects and divided into control group and research group according to the random number table method，with 53 cases in each group. The control group was given hyperbaric oxygen treatment for 20 days，while the research group was given Xingnaojing injection on the basis of the treatment in the control group for 20 days. The levels of hypersensitive C-reactive protein（hs-CRP），interleukin-6（IL-6），interleukin-10（IL-10），tumor necrosis factor - α（TNF - α），neuron specific enolase（NSE），5-hydroxytryptamine（5-HT），angiopoietin-2（Ang-2），inducible nitric oxide synthase（iNOS），malondialdehyde（MDA），superoxide dismutase（SOD）in the two groups were detected before and after treatment. The Montreal Cognitive Assessment Scale（MoCA），Mini-Mental State Examination（MMSE）and 36-Item Short Form Health Survey（SF-36）were used to evaluate the cognitive function and quality of life of the two groups of patients and to compare the clinical efficacy of the two groups after treatment.Results:The levels of hs CRP，TNF - α and IL-6 in the research group were lower than those in the control group（ P < 0.01），the level of IL-10 in the research group was higher than that in the control group（ P < 0.01），the level of 5-HT in the research group was higher than that in the control group（ P < 0.01），the levels of NSE，Ang-2，and iNOS in the research group were lower than those in the control group（ P < 0.01），the level of SOD in the research group was higher than that in the control group（ P < 0.01），and the level of MDA in the research group was lower than that in the control group（ P < 0.01）.The MMSE，MOCA and SF-36 scores of the research group were higher than those of the control group（ P < 0.01）. After treatment，the total effective rate of the research group（98.11%）was significantly higher than that of the control group（84.91%），and the difference was statistically significant（χ 2 = 4.371， P = 0.037）. Conclusion:Hyperbaric oxygen combined with Xingnaojing injection can improve the level of serum factors in patients with ACMPDE，inhibit inflammatory response，alleviate nerve injury，reduce oxidative stress response，and improve the cognitive function and the quality of life of patients，which is worthy of clinical application.

Objective:To observe the effects of hyperbaric oxygen combined with Xingnaojing injection on serum nerve injury，serum factors，and cognitive function in patients with acute carbon monoxide poisoning delayed encephalopathy（ACMPDE）.Methods:A total of 106 cases with ACMPDE who were admitted to the First People’s Hospital of Nanning from July 2018 to July 2020 were selected as the research subjects and divided into control group and research group according to the random number table method，with 53 cases in each group. The control group was given hyperbaric oxygen treatment for 20 days，while the research group was given Xingnaojing injection on the basis of the treatment in the control group for 20 days. The levels of hypersensitive C-reactive protein（hs-CRP），interleukin-6（IL-6），interleukin-10（IL-10），tumor necrosis factor - α（TNF - α），neuron specific enolase（NSE），5-hydroxytryptamine（5-HT），angiopoietin-2（Ang-2），inducible nitric oxide synthase（iNOS），malondialdehyde（MDA），superoxide dismutase（SOD）in the two groups were detected before and after treatment. The Montreal Cognitive Assessment Scale（MoCA），Mini-Mental State Examination（MMSE）and 36-Item Short Form Health Survey（SF-36）were used to evaluate the cognitive function and quality of life of the two groups of patients and to compare the clinical efficacy of the two groups after treatment.Results:The levels of hs CRP，TNF - α and IL-6 in the research group were lower than those in the control group（ P < 0.01），the level of IL-10 in the research group was higher than that in the control group（ P < 0.01），the level of 5-HT in the research group was higher than that in the control group（ P < 0.01），the levels of NSE，Ang-2，and iNOS in the research group were lower than those in the control group（ P < 0.01），the level of SOD in the research group was higher than that in the control group（ P < 0.01），and the level of MDA in the research group was lower than that in the control group（ P < 0.01）.The MMSE，MOCA and SF-36 scores of the research group were higher than those of the control group（ P < 0.01）. After treatment，the total effective rate of the research group（98.11%）was significantly higher than that of the control group（84.91%），and the difference was statistically significant（χ 2 = 4.371， P = 0.037）. Conclusion:Hyperbaric oxygen combined with Xingnaojing injection can improve the level of serum factors in patients with ACMPDE，inhibit inflammatory response，alleviate nerve injury，reduce oxidative stress response，and improve the cognitive function and the quality of life of patients，which is worthy of clinical application.

Allergic rhinitis (AR) is a global health problem that causes major illnesses and disabilities worldwide. Epidemiologic studies have demonstrated that the prevalence of AR has increased progressively over the last few decades in more developed countries and currently affects up to 40% of the population worldwide. Likewise, a rising trend of AR has also been observed over the last 2–3 decades in developing countries including China, with the prevalence of AR varying widely in these countries. A survey of self-reported AR over a 6-year period in the general Chinese adult population reported that the standardized prevalence of adult AR increased from 11.1% in 2005 to 17.6% in 2011. An increasing number of original articles and imporclinical trials on the epidemiology, pathophysiologic mechanisms, diagnosis, management and comorbidities of AR in Chinese subjects have been published in international peer-reviewed journals over the past 2 decades, and substantially added to our understanding of this disease as a global problem. Although guidelines for the diagnosis and treatment of AR in Chinese subjects have also been published, they have not been translated into English and therefore not generally accessible for reference to non-Chinese speaking international medical communities. Moreover, methods for the diagnosis and treatment of AR in China have not been standardized entirely and some patients are still treated according to regional preferences. Thus, the present guidelines have been developed by the Chinese Society of Allergy to be accessible to both national and international medical communities involved in the management of AR patients. These guidelines have been prepared in line with existing international guidelines to provide evidence-based recommendations for the diagnosis and management of AR in China.
Adult ; Asian Continental Ancestry Group* ; China ; Comorbidity ; Developed Countries ; Developing Countries ; Diagnosis* ; Epidemiologic Studies ; Epidemiology ; Global Health ; Humans ; Hypersensitivity* ; Prevalence ; Rhinitis, Allergic*